synaffix.com
About company
Synaffix BV is a clinical-stage, Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) that enables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035. Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products for their own pipelines. Disclosed partnerships to date include those with ADC Therapeutics and Mersana Therapeutics
